In the past week, CKPT stock has gone up by 6.79%, with a monthly gain of 31.03% and a quarterly surge of 67.19%. The volatility ratio for the week is 9.69%, and the volatility levels for the last 30 days are 9.06% for Checkpoint Therapeutics Inc The simple moving average for the past 20 days is 7.25% for CKPT’s stock, with a 67.63% simple moving average for the past 200 days.
Is It Worth Investing in Checkpoint Therapeutics Inc (NASDAQ: CKPT) Right Now?
CKPT has 36-month beta value of 1.28. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CKPT is 37.36M, and currently, short sellers hold a 14.89% ratio of that float. The average trading volume of CKPT on November 14, 2024 was 628.35K shares.
CKPT) stock’s latest price update
The stock of Checkpoint Therapeutics Inc (NASDAQ: CKPT) has increased by 2.07 when compared to last closing price of 3.62.Despite this, the company has seen a gain of 6.79% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates.
Analysts’ Opinion of CKPT
Many brokerage firms have already submitted their reports for CKPT stocks, with B. Riley Securities repeating the rating for CKPT by listing it as a “Buy.” The predicted price for CKPT in the upcoming period, according to B. Riley Securities is $7 based on the research report published on July 14, 2022 of the previous year 2022.
B. Riley Securities, on the other hand, stated in their research note that they expect to see CKPT reach a price target of $18. The rating they have provided for CKPT stocks is “Buy” according to the report published on June 09th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to CKPT, setting the target price at $16 in the report published on January 20th of the previous year.
CKPT Trading at 32.50% from the 50-Day Moving Average
After a stumble in the market that brought CKPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.93% of loss for the given period.
Volatility was left at 9.06%, however, over the last 30 days, the volatility rate increased by 9.69%, as shares surge +22.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +68.84% upper at present.
During the last 5 trading sessions, CKPT rose by +4.91%, which changed the moving average for the period of 200-days by +77.94% in comparison to the 20-day moving average, which settled at $3.44. In addition, Checkpoint Therapeutics Inc saw 61.35% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CKPT starting from Oliviero James F III, who sale 24,610 shares at the price of $2.05 back on Jun 26 ’24. After this action, Oliviero James F III now owns 1,977,170 shares of Checkpoint Therapeutics Inc, valued at $50,450 using the latest closing price.
GRAY WILLIAM GARRETT, the Chief Financial Officer of Checkpoint Therapeutics Inc, sale 13,038 shares at $2.06 during a trade that took place back on Jun 26 ’24, which means that GRAY WILLIAM GARRETT is holding 672,186 shares at $26,858 based on the most recent closing price.
Stock Fundamentals for CKPT
Current profitability levels for the company are sitting at:
- -798.17 for the present operating margin
- -451.68 for the gross margin
The net margin for Checkpoint Therapeutics Inc stands at -988.68. The total capital return value is set at 2.98.
Currently, EBITDA for the company is -52.15 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 3487.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.29.
Conclusion
To put it simply, Checkpoint Therapeutics Inc (CKPT) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
